first-line


Also found in: Medical.

first-line

(fûrst′līn′)
adj.
1.
a. Relating to or being the initial stage of something: the body's first-line defense against infection.
b. Being a drug or therapy that is the standard or initial treatment for a disease or condition.
2. Performing the most basic tasks or interacting directly with customers, patients, or clients; frontline.

first-line

adj
acting or used as a first resort: first-line treatment; first-line batsmen.
References in periodicals archive ?
Aduro Biotech announced that the first patient has been dosed in a Phase 2 clinical trial of ADU-S100, a novel STING pathway activator, in combination with KEYTRUDA, an approved anti-PD-1 antibody, as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma.The Phase 2, open-label, multicenter trial, which is part of an ongoing research and development collaboration with Novartis, is designed to evaluate the efficacy and safety of ADU-S100 administered intratumorally in combination with pembrolizumab in the first-line setting.
29, 2019 (HealthDay News) -- Currently, new anti-carbapenem-resistant Enterobacteriaceae (CRE) antibiotics are estimated to treat 35 percent of CRE infections in which they were expected to be used as first-line agents, according to a study published in the August issue of Open Forum Infectious Diseases.
NOTE OF CAUTION The organisation says it is updating its HIV therapy guidelines to strengthen its recommendation for dolutegravir (DTG) drug as the first-line treatment because of its efficacy, tolerability and a high genetic barrier to resistance.
M2 PHARMA-June 25, 2019-AstraZeneca and US Merck's Lynparza Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer
Global Banking News-June 20, 2019-AstraZeneca announces Japanese approval for Lynparza for first-line maintenance
M2 EQUITYBITES-June 20, 2019-AstraZeneca announces Japanese approval for Lynparza for first-line maintenance
- LYNPARZA Approved in the EU for Use as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer
Limited studies have been documented on the failures of first-line anti-retroviral therapy and hence the present study has been designed with an objective to determine the prevalence of failure of first-line anti-retroviral therapy in the study area.
The three key first-line drugs they studied are rifampicin, isoniazid and pyrazinamide.
(2-4) This role seems likely to expand considering the June 2016 publication of a study, first presented in part at previous American Society of Clinical Oncology and European Cancer Congress annual meetings, that found that patients with advanced NSCLC responded to nivolumab monotherapy as a first-line therapy.
Most evidence-based guidelines call for methotrexate (MTX) by itself as first-line therapy for rheumatoid arthritis (RA).